Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Endometrial Neoplasms 5Endometrial Hyperplasia 3Polycystic Ovary Syndrome 2Obesity 2Leiomyoma 2Infertility 2Overweight 1Ovarian Neoplasms 1Osteoporosis 1Neoplasms 1Myocardial Ischemia 1Heart Diseases 1Gliosarcoma 1Glioblastoma 1Coronary Disease 1Colonic Neoplasms 1Cardiovascular Diseases 1Breast Neoplasms 1Bone Diseases 1Anovulation 1

Interventions

telapristone acetate 18ulipristal acetate 17Uterine Myomectomy 13vilaprisan 12Leuprolide 11relugolix 9estradiol, norethindrone drug combination 9asoprisnil 9elagolix 7Uterine Artery Embolization 7Mifepristone 7Estradiol 7Bupivacaine 7ulipristal 6Tranexamic Acid 6Saline Solution 5Norethindrone Acetate 5linzagolix 4epigallocatechin gallate 4Sodium Chloride 4Letrozole 4Hysterectomy 4Vitamin B 6 3Sugars 3Misoprostol 3Lidocaine 3Gonadotropin-Releasing Hormone 3Embolization, Therapeutic 3cetrorelix 2Vitamin D 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Leiomyoma × Progestins × Clear all
NCT01156857 2016-01-15

PEARLIII

PregLem SA

Phase 3 Completed
209 enrolled

Leiomyoma

NCT01252069 2016-01-13

PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study)

PregLem SA

Phase 3 Completed
132 enrolled

Leiomyoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡